SCHEDULE: RA Capital Increases Stake in Climb Bio via PIPE

RA Capital Management disclosed a significant investment in Climb Bio, Inc. through a private placement of common stock and pre-funded warrants.

Summary

• RA Capital Management and affiliated entities acquired 2,106,000 pre-funded warrants in a private placement.
• The total consideration for the transaction was $20,006,789.40.
• The reporting persons now beneficially own 22,631,401 shares of Climb Bio, representing 33.0% of the outstanding common stock.
• The investment was funded by the working capital of the RA Capital Healthcare Fund.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal of institutional support, as a major investor is committing significant capital to the company's balance sheet.

Positives

• Strong institutional backing from RA Capital, a specialized healthcare investor.
• The private placement provides Climb Bio with immediate capital infusion of over $20 million.
• The investment demonstrates continued confidence from a major shareholder in the company's long-term prospects.

Negatives

• The issuance of new shares and warrants results in dilution for existing shareholders.
• Sera Medicines, LLC fell below the 5% beneficial ownership threshold due to the dilution caused by the private placement.

Risks

• Beneficial ownership is capped at 33.0% via a blocker provision in the pre-funded warrants.
• The company is subject to potential liquidated damages if it fails to meet registration statement filing deadlines.
• Market volatility could impact the value of the underlying common stock and the exercise of warrants.

Future Outlook

The company is obligated to file a registration statement for the resale of the shares and warrant shares within 45 days of the April 29, 2026 closing date.

Management Comments

• The reporting persons disclaim beneficial ownership of the securities reported other than for the purpose of determining their obligations under Section 13(d) of the Act.

Industry Context

StockSavvy.ai notes that this transaction follows a common trend in the biotech sector where institutional investors provide 'bridge' or 'growth' capital through private placements to support clinical development, often accompanied by registration rights to ensure liquidity for the investors.

Comparison to Industry Standards

• The use of pre-funded warrants is a standard mechanism in biotech PIPE transactions to allow investors to reach ownership caps without triggering immediate tax or regulatory hurdles.
• The 45-day registration deadline is consistent with standard market practice for private placements in the life sciences industry.

Stakeholder Impact

• Existing shareholders face dilution from the issuance of 9.48 million new shares and 2.1 million warrants.
• The company gains significant cash reserves to fund operations.

Next Steps

• Filing of a registration statement for the resale of the PIPE shares and warrant shares within 45 days of April 29, 2026.
• Potential exercise of pre-funded warrants subject to the 33% ownership blocker.

Key Dates

Recommendation

The capital raise provides necessary liquidity, but the significant dilution and the concentration of ownership by RA Capital suggest a period of consolidation for the stock price.

Keywords

Climb Bio, RA Capital, Private Placement, PIPE, Biotech, Schedule 13D, Equity Financing